Drug intelligence / Profile preview

ASC09F

Development stage: Unknown
Lead developer: Ascletis Pharma
Modality: Small Molecules
Administration: Oral

Overview

ASC09F is a fixed-dose combination (FDC) treatment for HIV that targets the HIV protease enzyme. It combines ASC09 (also known as TMC-310911) with ritonavir. ASC09 is structurally similar to darunavir and functions as an HIV protease inhibitor. It works by binding to the protease enzyme to inhibit the cleavage of Gag-Pol polyproteins and Gag polyproteins, preventing the formation of mature virus particles capable of infection. ASC09F has also been investigated for potential use against COVID-19.

Other names: ASC-09/ritonavirRitonavir/ASC-09

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on ASC09F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC09F.

Explore the full profile